Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Bin Xiao"'
Publikováno v:
Biological and Pharmaceutical Bulletin. 43:1046-1051
Beta-asarone (β-Asarone), the major component of Acorus tatarinowii Rhizoma, has been proved to be muti-pharmacological activities including anti-inflammation, and which is effective in protecting the central nervous system. However, the effect of
Autor:
Xijing Zhang, Dandan Cheng, Jiajia Wang, Haixing Zhong, Zhenhua Jiang, Zongping Fang, Ting Gu, Wugang Hou, Bin-Xiao Su, Yi Li, Haiyun Guo, Shiquan Wang
Publikováno v:
Brain research. 1757
Rosmarinic acid (RA), a natural polyphenol, possesses potent antioxidant and anti-inflammatory activities. To evaluate the ability of RA to cure ischemic stroke and post-stroke depression (PSD), rats were treated with various doses of RA after cerebr
Autor:
Xiao-ling Zhu, Xin Chen, Yu-Yuan Min, Yu Wang, Xu Li, Bin-Xiao Su, Wei Wang, Jia Huo, Jian-Ming Pei
Publikováno v:
Brain Research. 1659:113-120
Paraplegia caused by spinal cord ischemia is a severe complication following surgeries in the thoracic aneurysm. HMGB1 has been recognized as a key mediator in spinal inflammatory response after spinal cord injury. Electroacupuncture (EA) pretreatmen
Autor:
Ling-Lei Kong, Guo-Lin Shen, Zhi-Yuan Wang, Xiao-Mei Zhuang, Wei-Bin Xiao, Mei Yuan, Ze-Hui Gong, Hua Li
Publikováno v:
Frontiers in Pharmacology, Vol 7 (2016)
Frontiers in Pharmacology
Frontiers in Pharmacology
Thienorphine (TNP) is a novel partial opioid agonist that has completed phase II clinical evaluation as a promising drug candidate for the treatment of opioid dependence. Previous studies have shown that TNP and its glucuronide conjugate (TNP-G) unde
Autor:
Christina L. Addison, James Villeneuve, Khalid N. Al-Zahrani, Grant A. Howe, Mohamed Shaad Hasim, Bin Xiao, Luc A. Sabourin, Glenwood D. Goss, Huijun Zhao, Harmanjatinder S. Sekhon, Jim Dimitroulakos
Publikováno v:
PLoS ONE
PLoS ONE, Vol 11, Iss 3, p e0150567 (2016)
PLoS ONE, Vol 11, Iss 3, p e0150567 (2016)
Blockade of epidermal growth factor receptor (EGFR) activity has been a primary therapeutic target for non-small cell lung cancers (NSCLC). As patients with wild-type EGFR have demonstrated only modest benefit from EGFR tyrosine kinase inhibitors (TK